KLYGEFA™ (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients

Approval supported by PREVAIL Phase III results showing statistically significant and
clinically meaningful improvements in activities of daily living starting as early as
week one and sustained through one year

First and only approved dual-binding nanobody C5 inhibitor in the US, offering once-
weekly subcutaneous self-administration via autoinjector with rapid and sustained
disease control

Alexion, AstraZeneca Rare Disease’s KLYGEFA™ (gefurulimab-gaks) has been approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive. KLYGEFA is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.

The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal PREVAIL Phase III trial. Results from the trial showed that KLYGEFA met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). In addition to the week 26 prespecified results, clinical improvement was observed as early as week one.1

gMG is a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness.2 In the US, an estimated 98,500 people are diagnosed with gMG with 81,000 being AChR-positive.3

Kelly Gwathmey, MD, associate professor in the Department of Neurology’s Division of Neuromuscular Medicine at Columbia University Vagelos College of Physicians and Surgeons; member of the MGFA Medical & Scientific Advisory Council; and principal investigator in the trial at Virginia Commonwealth University, said: “gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals. In the PREVAIL Phase III trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection. With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition.”

Samantha Masterson, President & Chief Executive Officer, Myasthenia Gravis Foundation of America (MGFA), said: “For the gMG community, every new approved treatment represents more than a clinical advance; it also represents choice. Because no two patients experience gMG in the same way, expanding the range of options available is fundamental to how we improve lives. The MGFA welcomes this approval and the new possibilities it opens for those who have been seeking more independence and greater control of their treatment administration.”

Marc Dunoyer, Chief Executive Officer, Alexion, said: “The US approval of KLYGEFA delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector. We are proud to have discovered and developed this novel dual-binding nanobody, and look forward to soon delivering this pioneering innovation to adults with gMG in the US, offering the established efficacy and safety of C5 inhibition with added convenience.”

Scott Weintraub, Senior Vice President, Head of US Business, Alexion, said: “Alexion has been at the forefront of transforming care for people living with gMG, and the US approval of KLYGEFA marks another important step in that journey. Building on our leadership in C5 inhibition, KLYGEFA reflects our continued commitment to advancing innovation in ways that respond to the diverse needs of people living with this complex and unpredictable disease. We are proud to bring this new innovative treatment to the gMG community in the US.”

KLYGEFA was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab-cwvz in gMG. The percentage of participants with treatment emergent adverse events (TEAEs) was similar between those who received KLYGEFA and placebo, and most TEAEs observed were mild to moderate in severity (grade 1 or 2). The most common TEAEs seen in those receiving KLYGEFA were injection site reactions (12%), back pain (8%) and vomiting (5%).1

The data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.1

KLYGEFA is approved in the European Union (EU), Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.

INDICATION & IMPORTANT SAFETY INFORMATION for KLYGEFA™ (gefurulimab-gaks)

INDICATION
KLYGEFA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

  • Initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS
Serious Meningococcal Infections
KLYGEFA, a complement inhibitor, increases the patient’s susceptibility to serious, life-threatening or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of KLYGEFA therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent KLYGEFA therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including KLYGEFA. The benefits and risks of treatment with KLYGEFA, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis.

Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of KLYGEFA in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment.

KLYGEFA REMS 
Due to the risk of serious meningococcal infections, KLYGEFA is available only through a restricted program called KLYGEFA REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with the REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations 2 weeks prior to the first dose of KLYGEFA. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently, and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least 2 weeks prior to the first dose of KLYGEFA. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card at all times during and for 3 months following KLYGEFA treatment.

Further information is available at www.KlygefaREMS.com or 1-888-765-4747.

Other Serious Infections

KLYGEFA blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported in patients treated with complement inhibitors.

Administer vaccinations for the prevention of Streptococcus pneumoniae infection according to ACIP recommendations. Patients receiving KLYGEFA are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Serious infections, including fatal events, have been observed in Study 1 and its extension study [see Adverse Reactions (6.1)].

In patients with active systemic infections, monitor closely for worsening infection and consider discontinuing KLYGEFA if the infection worsens.

ADVERSE REACTIONS
Most common adverse reactions (≥10%) were injection site reactions (12%). Injection site reactions (ISRs) occurred in 14% (36/253) of KLYGEFA-treated patients in Study 1 and its extension study. In Study 1, ISRs observed in KLYGEFA-treated patients, including rash, erythema, and pruritus, were non-serious, and none led to discontinuation. One patient discontinued KLYGEFA due to an ISR in the extension study. Most ISRs occurred within 24 to 72 hours after the most recent KLYGEFA injection.

Hypersensitivity reactions, including rash and urticaria, occurred in patients treated with KLYGEFA across Study 1 and its extension study; none of these reactions resulted in treatment discontinuation. The majority of these reactions occurred within 24 to 72 hours after the most recent KLYGEFA injection.

Serious infections occurred in Study 1 and its extension study. There were 2 fatal infections in KLYGEFA-treated patients, including 1 case of dengue fever and 1 case of sepsis from a tooth infection associated with a dental procedure. A serious sepsis event due to Mycoplasma pneumoniae resulted in KLYGEFA discontinuation. Three serious cases of diverticulitis, including 2 with abscesses, led to intestinal perforation in the KLYGEFA-treated patients; 2 of these patients had a prior history of diverticulitis.

DRUG INTERACTIONS
Use with PE or PP
Concomitant use of KLYGEFA with plasma exchange (PE) or plasmapheresis (PP) treatment has been shown to reduce serum gefurulimab concentrations and requires a supplemental dose of KLYGEFA.

Use with Neonatal Fc Receptor (FcRn) Inhibitors
Concomitant use of KLYGEFA with FcRn inhibitors that cause reductions in serum albumin should be monitored as concomitant use may lower systemic exposure to KLYGEFA and reduce its effectiveness.

USE IN SPECIFIC POPULATIONS
Treatment of pregnant women with KLYGEFA should only be considered if the clinical benefit outweighs the risks. Report pregnancies to the Alexion Pharmaceuticals, Inc. adverse event reporting line at 1-844-259-6783.

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for KLYGEFA, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Notes

Generalized Myasthenia Gravis (gMG)
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness.2

Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control.4 This binding activates the complement system, causing the immune system to attack the NMJ, leading to inflammation and a breakdown in communication between the brain and the muscles.5

gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60.6 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses, such as impaired swallowing, choking, extreme fatigue and respiratory failure.7,8

PREVAIL (ALXN1720-MG-301)
PREVAIL (ALXN1720-MG-301) is a global, Phase III, randomized, double-blind, placebo-controlled, parallel, multicenter study evaluating the safety and efficacy of KLYGEFA™ (gefurulimab-gaks) in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients from 20 countries across North America, Europe, Asia and the Pacific region. Participants were required to have a confirmed myasthenia gravis diagnosis at least three months prior to the screening visit with a positive serological test for autoantibodies against AChR and Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.9

Patients were randomized 1:1 to receive KLYGEFA or placebo for a total of 26 weeks in the randomized controlled treatment period. Patients received a single weight-based loading dose on Day 1, followed by regular weight-based maintenance dosing beginning on Day 8 and once every week thereafter. The primary endpoint of the change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a patient-reported scale that assesses patients’ abilities to perform daily activities, was assessed at week 26 along with multiple secondary endpoints evaluating improvement in disease-related measures.9

Patients who completed the randomized controlled treatment period were eligible to continue into an open-label extension period evaluating the safety and efficacy of KLYGEFA, which is ongoing.9

KLYGEFA™ (gefurulimab-gaks)
KLYGEFA™ (gefurulimab-gaks), a complement C5 inhibitor, is a novel dual-binding nanobody optimized for subcutaneous self-administration for the treatment of AChR-Ab+ gMG. The medication works by binding to the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. KLYGEFA’s concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing. 

KLYGEFA is approved in the European Union (EU), Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.

Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. For more information, please visit www.alexion.us.

AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.

Media Inquiries
US Media Mailbox: usmediateam@astrazeneca.com

References

  1. Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. 2026 Jul 27.
  2. Jung-Plath W, et al. Assessment of myasthenia gravis patients’ quality of life. The Journal of Neurosurgical Nursing. 2023;12(2):74-83.
  3. AstraZeneca Data on File - Epidemiology estimates are composed of a triangulation of different data sources including Data Monitor, Decision Resources Group, Kantar Health, and internal input. Available here. Accessed November 2026.
  4. Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.
  5. Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024.
  6. Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
  7. Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019.
  8. Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54.
  9. ClinicalTrials.gov. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. NCT Identifier: NCT05556096. Available here. Accessed November 2026.